ISSN: 1859 - 2872
The result of treatment for early-stage non-small cell lung cancer patients by stereotactic body radiation therapy
Main Article Content
Keywords
Abstract
Objective: To evaluate the result of treatment for stage I NSCLC patients (T1-2aN0M0) inoperable by SBRT. Subject and method: Prospective, follow-up 32 patients with stage T1-2aN0M0 NSCLC with peripheral tumor, who were received SBRT, follow-up and evaluated from January 2015 to November 2021. The primary endpoint was progression free survival (PFS), the second endpoints were overall survival (OS), the OS rate in 1, 2, 3, 4 and 5 years, and toxicity. Result: The median age was 67 years-old, the median of diameter was 2.65cm, the mean of SUVmax value was 7.95, the stage of the tumor was mostly T2a (43.7%). The median PFS was 29 months, PFS in 2 years and 3 years were 59.8% and 42.3%, respectively. The median OS was 59 months, the ratio of OS in 1 year, 2 years, 3 years, 4 years, 5 years were 96.8%, 88.6%, 84.2%, 63.1% and 42.1%, respectively. Patients who achieved disease control according to PERCIST 1.0 criteria reduced the risk of death with HR = 0.053 (95% CI: 0.003-0.86), p=0.039. The median PFS in the SUVmax < 5 group was longer than that in the SUVmax ≥ 5 group, p=0.032. Cyfra 21-1 before and after SBRT, tumor size were prognostic factors for survival. The common of adverse events was pneumonitis at 10 patients, but mainly was grade 1 and grade 2, there are no patients with grade 4 and grade 5 pneumonitis. No clinically significant changes in pulmonary function following SBRT. Conclusion: SBRT was a good option for patients with early-stage NSCLC inoperable with peripheral tumor. The SUVmax value before treatment, the disease control rate at 3 months after SBRT according to PERCIST 1.0 and Cyfra 21-1 criteria before and after treatment were the predictors of the patient's survival. And SBRT was a safe method.
Article Details
References
2. Schneider BJ, Daly ME, Kennedy EB et al (2017) Stereotactic Body Radiation Therapy for Early-stage non-small cell lung cancer: American Society for Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 36: 710-719.
3. Shinde A, Li R, Kim J et al (2018) Stereotactic Body Radiation Therapy (SBRT) for early-stage lung cancer in the elderly. Seminars in Oncology 45: 210-219.
4. Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II Study. Int J Radiat Oncol Biol Phys 75(3): 677-682.
5. Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7): 1623-1631.
6. Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic Body Radiation Therapy for Inoperable Early-Stage Lung Cancer. JAMA 303(11): 1070-1076.
7. Nagata Y, Hiraoka M, Shibata T et al (2012) Stereotactic Body Radiation Therapy for T1N0M0 Non-small Cell Lung Cancer First Report for Inoperable Population of a Phase II Trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys 84: 46-46.
8. Ricardi U, Filippi AR, Guarneri A et al (2010) Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Results of a prospective trial. Lung cancer 68(1): 72-77.
9. Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a Prospective Phage II Trial of Medically Inoperable stage I non-small cell lung cancer patients treated with Stereotactic Body Radiation Therapy, J Clin Oncol 27: 3290-3296.
10. Christopher GC, Greenberg ER, Baron J et al (1985) Presenting conditions of i539 population-based lung cancer patients by cell type and stage in new hampshire and vermont. Cancer 56: 2107-2111.
11. Timmerman RD, Paulus R, Pass HI et al (2018) Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG oncology RTOG 0618 trial. JAMA Oncol 4: 1263-1266.
12. Zheng X, Schipper M, Kidwell K et al (2014) Survival outcome after stereotactic body radiation therapy and surgery for stage i non-small cell lung cancer: A meta-analysis. International Journal of Radiation Oncology Biology Physics 90(3): 603-611.
13. Takeda K, Takanami K, Shirata Y et al (2017) Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy. Journal of Radiation Research 58(6): 862-869.
14. Sheikhbahaei S, Mena E, Yanamadala A et al (2017) The value of FDG PET/CT in treatment response assessment, follow-up, and surveillance of lung cancer. AJR 208: 420-433.
15. Lê Hải Sơn, Trần Trọng Kiểm, Mai Văn Viện, Ngô Vi Hải (2022) Mối liên quan giữa di căn hạch với sống thêm toàn bộ sau phẫu thuật nội soi lồng ngực điều trị ung thư phổi không tế bào nhỏ. Tạp chí Y Dược lâm sàng 108, tập 17, số 1, tr. 108-113.
16. Trần Minh Bảo Luân, Vũ Chí Thanh (2018) Các yếu tố tiên lượng thời gian sống còn sau phẫu thuật điều trị ung thư phổi không tế bào nhỏ. Tạp chí Phẫu thuật tim mạch và lồng ngực Việt Nam, 23, tr. 75-85.
17. Pierson C, Grinchak T, Sokolovic C et al (2018) Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. Radiation Oncology 13: 34.
18. Horne ZD, Clump DA, Vargo JA et al (2014) Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiation Oncology 9: 41.
19. Shintani T, Matsuo Y, Iizuka Y et al (2017) Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy. Anticancer Research 37: 5161-5167.
20. Stanic S, Paulus R, Timmerman RD et al (2014) No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 88(5): 1092-1099.
Article Sidebar
